Carcinogenesis, Vol. 23, No. 1, 201-205,
January 2002
© 2002 Oxford University Press
SHORT COMMUNICATION |
AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis
1 Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE,
2 Department Creighton University, Department of Hereditary Cancer, Omaha, NE,
3 Department of Pathology, Mayo Clinic, Rochester, MN, USA
The inhibition of apoptosis is a critical event in the development of colorectal malignancies, although the mechanism(s) remain incompletely understood. The anti-apoptotic proto-oncogene, AKT, has been implicated in the molecular pathogenesis of a variety of human malignancies; however, no data exist on the role of AKT in colon carcinogenesis. We therefore evaluated the presence of AKT in human and experimental colon neoplasms by immunohistochemistry. Normal colonic mucosa and hyperplastic polyps exhibited no significant AKT expression, in marked contrast to the dramatic AKT immunoreactivity seen in colorectal cancers (57% positive) and in both human colorectal cancer cell lines examined. Importantly, AKT was also detected in 57% of the adenomas examined, implicating overexpression of this proto-oncogene as an early event during colon carcinogenesis. Moreover, in the rodent-carcinogen model, azoxymethane (AOM)-treatment induced AKT expression in premalignant rat colonocytes. Tumors that evolve via different genetic pathways displayed a lower incidence of AKT overexpression. Indeed, only 22% of mismatch repair defective tumors and 42% of AOM-induced rodent tumors upregulated AKT. Staining with an antibody specific for AKT 2 duplicated findings with the AKT 1&2 antibody, suggesting that AKT 2 was the predominant isoform involved in colon carcinogenesis. Furthermore, utilizing an antibody that specifically recognizes the serine-473 phosphorylated form of AKT, we observed that activated AKT was detectable in the neoplastic but not normal epithelium.
In summary, our immunohistochemical analysis indicates AKT overexpression occurs frequently during human colon carcinogenesis, but is less common in colon cancers with microsatellite instability. The early inhibition of apoptosis during sporadic colon carcinogenesis may be related, at least partly, to the overexpression of AKT.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S.-W. Shin, C.-Y. Seo, H. Han, J.-Y. Han, J.-S. Jeong, J.-Y. Kwak, and J.-I. Park 15d-PGJ2 Induces Apoptosis by Reactive Oxygen Species-mediated Inactivation of Akt in Leukemia and Colorectal Cancer Cells and Shows In vivo Antitumor Activity Clin. Cancer Res., September 1, 2009; 15(17): 5414 - 5425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-J. LIU and R.-D. DUAN LY294002 Enhances Boswellic Acid-induced Apoptosis in Colon Cancer Cells Anticancer Res, August 1, 2009; 29(8): 2987 - 2991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. JOHNSON, P. GULHATI, I. ARRIETA, X. WANG, T. UCHIDA, T. GAO, and B. M. EVERS Curcumin Inhibits Proliferation of Colorectal Carcinoma by Modulating Akt/mTOR Signaling Anticancer Res, August 1, 2009; 29(8): 3185 - 3190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Loupakis, L. Pollina, I. Stasi, A. Ruzzo, M. Scartozzi, D. Santini, G. Masi, F. Graziano, C. Cremolini, E. Rulli, et al. PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer J. Clin. Oncol., June 1, 2009; 27(16): 2622 - 2629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sachdeva, S. Zhu, F. Wu, H. Wu, V. Walia, S. Kumar, R. Elble, K. Watabe, and Y.-Y. Mo p53 represses c-Myc through induction of the tumor suppressor miR-145 PNAS, March 3, 2009; 106(9): 3207 - 3212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Warren, K. J. Paulhill, L. A. Davidson, J. R. Lupton, S. S. Taddeo, M. Y. Hong, R. J. Carroll, R. S. Chapkin, and N. D. Turner Quercetin May Suppress Rat Aberrant Crypt Foci Formation by Suppressing Inflammatory Mediators That Influence Proliferation and Apoptosis J. Nutr., January 1, 2009; 139(1): 101 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Rizzieri, E. Feldman, J. F. DiPersio, N. Gabrail, W. Stock, R. Strair, V. M. Rivera, M. Albitar, C. L. Bedrosian, and F. J. Giles A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies Clin. Cancer Res., May 1, 2008; 14(9): 2756 - 2762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A Dennis Targeting Akt in Cancer: Promise, Progress, and Potential Pitfalls Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 25 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F.L. O'Shaughnessy, B. Akgul, A. Storey, H. Pfister, C. A. Harwood, and C. Byrne Cutaneous Human Papillomaviruses Down-regulate AKT1, whereas AKT2 Up-regulation and Activation Associates with Tumors Cancer Res., September 1, 2007; 67(17): 8207 - 8215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ma, J. Teruya-Feldstein, P. Bonner, R. Bernardi, D. N. Franz, D. Witte, C. Cordon-Cardo, and P. P. Pandolfi Identification of S664 TSC2 Phosphorylation as a Marker for Extracellular Signal-Regulated Kinase Mediated mTOR Activation in Tuberous Sclerosis and Human Cancer Cancer Res., August 1, 2007; 67(15): 7106 - 7112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Crowell, V. E. Steele, and J. R. Fay Targeting the AKT protein kinase for cancer chemoprevention Mol. Cancer Ther., August 1, 2007; 6(8): 2139 - 2148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Kopelovich, J. R. Fay, C. C. Sigman, and J. A. Crowell The Mammalian Target of Rapamycin Pathway as a Potential Target for Cancer Chemoprevention Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1330 - 1340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Z. Cheng, J. Chan, Q. Wang, W. Zhang, C. D. Sun, and L.-H. Wang Twist Transcriptionally Up-regulates AKT2 in Breast Cancer Cells Leading to Increased Migration, Invasion, and Resistance to Paclitaxel Cancer Res., March 1, 2007; 67(5): 1979 - 1987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dihlmann, M. Kloor, C. Fallsehr, and M. von Knebel Doeberitz Regulation of AKT1 expression by beta-catenin/Tcf/Lef signaling in colorectal cancer cells Carcinogenesis, September 1, 2005; 26(9): 1503 - 1512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. DeFeo-Jones, S. F. Barnett, S. Fu, P. J. Hancock, K. M. Haskell, K. R. Leander, E. McAvoy, R. G. Robinson, M. E. Duggan, C. W. Lindsley, et al. Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members Mol. Cancer Ther., February 1, 2005; 4(2): 271 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Peng, S.-M. Liang, and C.-M. Liang VP1 of Foot-and-Mouth Disease Virus Induces Apoptosis via the Akt Signaling Pathway J. Biol. Chem., December 10, 2004; 279(50): 52168 - 52174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Narayanan, N. K. Narayanan, B. Pittman, and B. S. Reddy Regression of Mouse Prostatic Intraepithelial Neoplasia by Nonsteroidal Anti-inflammatory Drugs in the Transgenic Adenocarcinoma Mouse Prostate Model Clin. Cancer Res., November 15, 2004; 10(22): 7727 - 7737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Balsara, J. Pei, Y. Mitsuuchi, R. Page, A. Klein-Szanto, H. Wang, M. Unger, and J. R. Testa Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions Carcinogenesis, November 1, 2004; 25(11): 2053 - 2059. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Moran, D. H. Hunt, S. H. Javid, M. Redston, A. M. Carothers, and M. M. Bertagnolli Apc Deficiency Is Associated with Increased Egfr Activity in the Intestinal Enterocytes and Adenomas of C57BL/6J-Min/+ Mice J. Biol. Chem., October 8, 2004; 279(41): 43261 - 43272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. K. Roy, P. Iversen, J. Hart, Y. Liu, J. L. Koetsier, Y. Kim, D. P. Kunte, M. Madugula, V. Backman, and R. K. Wali Down-regulation of SNAIL suppresses MIN mouse tumorigenesis: Modulation of apoptosis, proliferation, and fractal dimension Mol. Cancer Ther., September 1, 2004; 3(9): 1159 - 1165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G.-i. Kusakai, A. Suzuki, T. Ogura, S.'i. Miyamoto, A. Ochiai, M. Kaminishi, and H. Esumi ARK5 Expression in Colorectal Cancer and Its Implications for Tumor Progression Am. J. Pathol., March 1, 2004; 164(3): 987 - 995. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Khaleghpour, Y. Li, D. Banville, Z. Yu, and S.-H. Shen Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma Carcinogenesis, February 1, 2004; 25(2): 241 - 248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Toyosawa, K. Tanaka, T. Imai, K. Yasuhara, T. Koujitani, M. Hirose, and K. Mitsumori Mutation and Overexpression of the Transgene in Ethylnitrosourea-Induced Tumors in Mice Carrying a Human Prototype c-Ha-ras Gene Toxicol Pathol, August 1, 2003; 31(5): 491 - 495. [Abstract] [PDF]
|
|
|
|
|
|
A. S. Tsao, T. McDonnell, S. Lam, J. B. Putnam, N. Bekele, W. K. Hong, and J. M. Kurie Increased Phospho-AKT (Ser473) Expression in Bronchial Dysplasia: Implications for Lung Cancer Prevention Studies Cancer Epidemiol. Biomarkers Prev., July 1, 2003; 12(7): 660 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Arboleda, J. F. Lyons, F. F. Kabbinavar, M. R. Bray, B. E. Snow, R. Ayala, M. Danino, B. Y. Karlan, and D. J. Slamon Overexpression of AKT2/Protein Kinase B{beta} Leads to Up-Regulation of {beta}1 Integrins, Increased Invasion, and Metastasis of Human Breast and Ovarian Cancer Cells Cancer Res., January 1, 2003; 63(1): 196 - 206. [Abstract] [Full Text] [PDF]
|
|